Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
PROTEINA logo — Our Protein-protein interaction (PPI) analysis platform enab...

PROTEINA

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the single-molecule level

Founded 2015 Korea South Korea South 32 employees Series C Total: $19.00B Biotechnology, Health Care +2

General Information

Company Name PROTEINA
Founded Year 2015
Location Korea South Korea South
Employees 32
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with PROTEINA. To contact PROTEINA, visit proteina.co.kr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PROTEINA compare?

A PDF of PROTEINA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PROTEINA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PROTEINA

PROTEINA is a biotechnology startup based in South Korea, founded in 2015. The company has revolutionized protein analysis with its first-in-class protein-protein interaction (PPI) analysis platform, utilizing proprietary 'single-molecule co-immunoprecipitation' technology for quantitative measurements at the single-molecule level. This innovative platform provides unmatched accuracy and speed in analyzing PPIs, thereby paving the way for new approaches to diagnosing diseases and discovering drug candidates. In its latest funding round in July 2021, PROTEINA secured a significant KRW19.00B Series C investment, attracting a diverse group of investors including LB Investment, Aju IB Investment, Mirae Asset Venture Investment, GNTech VC, Mirae Asset Capital, Posco Capital, Timefolio Asset Management, and K-Run Ventures. This notable investment underscores the confidence of the venture capital community in the potential of PROTEINA's innovative technology and its impact on the biotechnology, healthcare, and pharmaceutical industries. With its extensive expertise in developing assays to measure targeted PPIs and the ability to model drug efficacy based on PPI metrics, PROTEINA is poised to drive significant advances in the understanding and treatment of diseases. Consequently, the company stands as a compelling investment opportunity at the forefront of revolutionizing protein analysis and contributing to advancements in the biotechnology and pharmaceutical sectors. For more information regarding PROTEINA, please visit their website at www.proteina.co.kr.

Business keywords: protein-protein interaction, PPI analysis, single-molecule co-immunoprecipitation, quantitative measurements, drug efficacy modeling, protein analysis, disease diagnostics, drug discovery, biotech startup, molecular analysis, diagnostic technology, pharmaceutical research, biomedical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C KRW19.00B 8
LB Investment Aju IB Investment Mirae Asset Venture Investment
LB Investment, Aju IB Investment +6
05 Jul 2021
Venture Round Undisclosed 1
KNet Investment Partners
KNet Investment Partners
08 Oct 2018

PROTEINA Alternatives & Competitors

View All Alternatives
PROTEINA vs
Tangram Therapeutics
Tangram Therapeutics United Kingdom

Relentless medicine discovery.

Venture round
32 employees
Biotechnology, Health Care
Compare PROTEINA vs Tangram Therapeutics
PROTEINA vs
Degron Therapeutics
Degron Therapeutics United States

Aims to become a global leader in the discovery and development of molecular glue degraders

Series A
25 employees
Biotechnology, Health Care
Compare PROTEINA vs Degron Therapeutics
PROTEINA vs
Protai
Protai Israel

Proteomics & AI Drug discovery

Seed
29 employees
AI, Biotechnology
Compare PROTEINA vs Protai
Also compare with: PROTEINA vs Quantum-Si Quantum-Si PROTEINA vs Refeyn Refeyn View all alternatives

FAQ About PROTEINA

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the single-molecule level
PROTEINA was founded in 2015.
PROTEINA is headquartered in Korea South.
PROTEINA operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on protein-protein interaction, PPI analysis, single-molecule co-immunoprecipitation and quantitative measurements.
PROTEINA has approximately 32 employees.
PROTEINA has completed 2 funding rounds, raising a total of $19.00B. The latest funding stage is Series C.
Top alternatives and competitors to PROTEINA include Tangram Therapeutics, Degron Therapeutics, Protai, Complix N.V., Quantum-Si. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PROTEINA and Tangram Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PROTEINA, https://bouncewatch.com/company/proteina, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes